Yvonne Anderson

ORCID: 0009-0004-6117-0641
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immune Cell Function and Interaction
  • Cancer survivorship and care
  • Diabetes and associated disorders
  • Toxin Mechanisms and Immunotoxins
  • T-cell and B-cell Immunology
  • Monoclonal and Polyclonal Antibodies Research
  • Health and Wellbeing Research
  • HIV Research and Treatment
  • Immunodeficiency and Autoimmune Disorders
  • Synthesis and Biological Evaluation
  • Endometrial and Cervical Cancer Treatments

Queen Elizabeth Hospital
2025

Harvard University
1988

Dana-Farber Cancer Institute
1988

The Rpt-1 (for regulatory protein, T-lymphocyte, 1) gene, selectively expressed by resting but not activated CD4+ inducer T cells, encodes an intracellular protein (rpt-1, Mr 41,000) that down-regulates gene expression directed the promoter region of encoding interleukin 2 receptor alpha chain and long terminal repeat human immunodeficiency virus type 1. data reported here suggest rpt-1 levels may be inversely correlated with activation cells replication leading to clinical symptoms acquired...

10.1073/pnas.85.8.2733 article EN Proceedings of the National Academy of Sciences 1988-04-01

Introduction: Vulvar cancer affects approximately 47,000 women annually worldwide. With most studies focusing on oncological outcomes, quality of life is often overlooked. There a lack knowledge the influence modifiable factors such as lifestyle vulvar survivors. This study evaluated association between and Methods: was cross-sectional survey who received surgical treatment for ≥FIGO stage 1B at Northern Gynecological Oncology Centre, UK, 2013 2022. Baseline clinical characteristics were...

10.3390/cancers17061024 article EN Cancers 2025-03-18

13505 Background: Immunotoxins (ITs) has shown limited clinical success related to liver toxicity and development of anti-IT antibodies. To delay the immune response we tested combinations ITs Cyclosporin A (CsA). have that one IT, currently in a phase I/II trial, acts by inducing apoptosis protein synthesis inhibition, but gene expression analysis IT treated cells never been reported. Hence, also studied changes induced alone effects adding (CsA) on both treatment efficacy signature....

10.1200/jco.2007.25.18_suppl.13505 article EN Journal of Clinical Oncology 2007-06-20
Coming Soon ...